Amylyx’s efforts to explore other indications for Relyvrio seems to be bearing fruit: GlobalData Read more
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial Read more
Puma Biotechnology announces presentation of findings from a phase II study of alisertib in endocrine-resistant metastatic breast cancer Read more